{
  "schema_version": "1.0.0",
  "last_updated": "2025-02-09",
  "disclaimer": "This database is for informational purposes only. Always verify requirements with official regulatory sources.",
  "markets": {
    "FDA": {
      "name": "U.S. Food and Drug Administration",
      "region": "United States",
      "official_sources": [
        "https://www.fda.gov/medical-devices",
        "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-807",
        "https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance"
      ],
      "device_classifications": {
        "Class I": {
          "risk_level": "Low",
          "requirements": [
            "Establishment Registration (21 CFR 807)",
            "Device Listing (21 CFR 807)",
            "General Controls (21 CFR 820)",
            "Labeling Requirements (21 CFR 801)",
            "Medical Device Reporting (21 CFR 803)"
          ],
          "submission_required": false,
          "premarket_notification_510k": false,
          "premarket_approval_pma": false,
          "typical_timeline_months": 2
        },
        "Class II": {
          "risk_level": "Moderate",
          "requirements": [
            "Establishment Registration (21 CFR 807)",
            "Device Listing (21 CFR 807)",
            "Quality System Regulation (21 CFR 820)",
            "510(k) Premarket Notification",
            "Labeling Requirements (21 CFR 801)",
            "Medical Device Reporting (21 CFR 803)"
          ],
          "submission_required": true,
          "premarket_notification_510k": true,
          "premarket_approval_pma": false,
          "typical_timeline_months": 4
        },
        "Class III": {
          "risk_level": "High",
          "requirements": [
            "Establishment Registration (21 CFR 807)",
            "Device Listing (21 CFR 807)",
            "Quality System Regulation (21 CFR 820)",
            "Premarket Approval (PMA)",
            "Labeling Requirements (21 CFR 801)",
            "Medical Device Reporting (21 CFR 803)",
            "Postmarket Surveillance"
          ],
          "submission_required": true,
          "premarket_notification_510k": false,
          "premarket_approval_pma": true,
          "typical_timeline_months": 12
        }
      },
      "special_programs": {
        "Breakthrough Device": {
          "description": "Expedited review for breakthrough technologies",
          "timeline_reduction": "30-50%",
          "requirements": ["More effective than available technology", "Life-threatening or irreversibly debilitating"]
        },
        "De Novo": {
          "description": "Premarket review for low-moderate risk devices",
          "timeline_months": 6,
          "requirements": ["No predicate device", "General controls insufficient"]
        }
      }
    },
    "EU_MDR": {
      "name": "European Union Medical Device Regulation",
      "region": "European Union",
      "official_sources": [
        "https://health.ec.europa.eu/medical-devices-sector/new-regulations_en",
        "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0745",
        "https://health.ec.europa.eu/medical-devices-new-regulations/guidance_en"
      ],
      "device_classifications": {
        "Class I": {
          "risk_level": "Low",
          "requirements": [
            "Technical Documentation (Annex II)",
            "Declaration of Conformity (Annex IV)",
            "General Safety and Performance Requirements (Annex I)",
            "Post-Market Surveillance (Article 83-85)",
            "Registration in EUDAMED",
            "Labeling per Article 23"
          ],
          "notified_body_required": false,
          "clinical_evaluation_required": true,
          "typical_timeline_months": 3
        },
        "Class IIa": {
          "risk_level": "Low-Medium",
          "requirements": [
            "Technical Documentation (Annex II)",
            "Declaration of Conformity (Annex IV)",
            "Intervention of Notified Body",
            "General Safety and Performance Requirements (Annex I)",
            "Clinical Evaluation (MEDDEV 2.7.1)",
            "Post-Market Surveillance (Article 83-85)",
            "Registration in EUDAMED"
          ],
          "notified_body_required": true,
          "clinical_evaluation_required": true,
          "typical_timeline_months": 6
        },
        "Class IIb": {
          "risk_level": "Medium-High",
          "requirements": [
            "Technical Documentation (Annex II)",
            "Declaration of Conformity (Annex IV)",
            "Intervention of Notified Body",
            "General Safety and Performance Requirements (Annex I)",
            "Clinical Evaluation Report (MEDDEV 2.7.1 rev 4)",
            "Post-Market Surveillance (Article 83-85)",
            "Periodic Safety Update Report (Annex XIII)",
            "Registration in EUDAMED"
          ],
          "notified_body_required": true,
          "clinical_evaluation_required": true,
          "typical_timeline_months": 9
        },
        "Class III": {
          "risk_level": "High",
          "requirements": [
            "Technical Documentation (Annex II)",
            "Declaration of Conformity (Annex IV)",
            "Notified Body Assessment",
            "Clinical Investigation (unless justified)",
            "General Safety and Performance Requirements (Annex I)",
            "Clinical Evaluation Report (MEDDEV 2.7.1 rev 4)",
            "Post-Market Surveillance (Article 83-85)",
            "Periodic Safety Update Report (Annex XIII)",
            "Post-Market Clinical Follow-up (Article 86)",
            "Registration in EUDAMED"
          ],
          "notified_body_required": true,
          "clinical_evaluation_required": true,
          "typical_timeline_months": 12
        }
      },
      "special_programs": {
        "Conditional Approval": {
          "description": "Early access for unmet medical needs",
          "requirements": ["Serious disease", "No satisfactory alternative", "Benefit-risk positive"]
        }
      }
    },
    "MFDS": {
      "name": "Ministry of Food and Drug Safety (South Korea)",
      "region": "South Korea",
      "official_sources": [
        "https://www.mfds.go.kr/eng",
        "https://www.mfds.go.kr/en/index.do",
        "https://ec.europa.eu/growth/tools-databases/tariic/interdependent-instruments/163"
      ],
      "device_classifications": {
        "Class I": {
          "risk_level": "Low",
          "requirements": [
            "Establishment Registration",
            "Device Registration",
            "Supplier Verification",
            "Labeling Requirements (MFDS Notice)"
          ],
          "submission_required": false,
          "typical_timeline_months": 2
        },
        "Class II": {
          "risk_level": "Moderate",
          "requirements": [
            "Establishment Registration",
            "Device Registration",
            "Quality Management System (KGMP)",
            "Submission for Approval",
            "Labeling Requirements"
          ],
          "submission_required": true,
          "typical_timeline_months": 4
        },
        "Class III": {
          "risk_level": "High",
          "requirements": [
            "Establishment Registration",
            "Device Registration",
            "KGMP Certification",
            "Submission for Approval",
            "Clinical Data Requirement",
            "Labeling Requirements"
          ],
          "submission_required": true,
          "typical_timeline_months": 8
        },
        "Class IV": {
          "risk_level": "Very High",
          "requirements": [
            "Establishment Registration",
            "Device Registration",
            "KGMP Certification",
            "Submission for Approval",
            "Clinical Investigation",
            "Labeling Requirements"
          ],
          "submission_required": true,
          "typical_timeline_months": 12
        }
      },
      "special_programs": {
        "Innovative Medical Device": {
          "description": "Fast-track for innovative devices",
          "timeline_reduction": "30%",
          "requirements": ["Novel technology", "Unmet medical need"]
        }
      }
    },
    "PMDA": {
      "name": "Pharmaceuticals and Medical Devices Agency (Japan)",
      "region": "Japan",
      "official_sources": [
        "https://www.pmda.go.jp/english/",
        "https://www.mhlw.go.jp/english/",
        "https://www.pmda.go.jp/review-services/drug-reviews/foreign-manufacturers/0003.html"
      ],
      "device_classifications": {
        "Class I": {
          "risk_level": "Low",
          "requirements": [
            "Business Registration",
            "Device Listing",
            "General Safety Requirements"
          ],
          "submission_required": false,
          "typical_timeline_months": 2
        },
        "Class II": {
          "risk_level": "Moderate",
          "requirements": [
            "Business Registration",
            "Device Certification by Registered Certification Body",
            "Quality Management System",
            "Pre-market Certification"
          ],
          "submission_required": true,
          "typical_timeline_months": 6
        },
        "Class III": {
          "risk_level": "High",
          "requirements": [
            "Business Registration",
            "PMDA Pre-market Approval",
            "Quality Management System",
            "Clinical Data",
            "Review by PMDA"
          ],
          "submission_required": true,
          "typical_timeline_months": 12
        },
        "Class IV": {
          "risk_level": "Very High",
          "requirements": [
            "Business Registration",
            "PMDA Pre-market Approval",
            "Quality Management System",
            "Clinical Investigation",
            "Priority Review"
          ],
          "submission_required": true,
          "typical_timeline_months": 15
        }
      },
      "special_programs": {
        "Priority Review": {
          "description": "Expedited review for innovative devices",
          "timeline_reduction": "40%",
          "requirements": ["Life-threatening", "No alternative", "Significant improvement"]
        },
        "Sakigake": {
          "description": "Pioneer review for innovative Japanese products",
          "timeline_reduction": "50%",
          "requirements": ["Japanese innovation", "World's first"]
        }
      }
    },
    "ANVISA": {
      "name": "National Health Surveillance Agency (Brazil)",
      "region": "Brazil",
      "official_sources": [
        "http://portal.anvisa.gov.br/english",
        "http://portal.anvisa.gov.br/documents",
        "https://www.gov.br/anvisa/pt-br"
      ],
      "device_classifications": {
        "Class I": {
          "risk_level": "Low",
          "requirements": [
            "GMP Certification",
            "Registration",
            "Technical File"
          ],
          "submission_required": true,
          "typical_timeline_months": 4
        },
        "Class II": {
          "risk_level": "Moderate",
          "requirements": [
            "GMP Certification",
            "Registration",
            "Technical File",
            "Safety and Performance Evidence"
          ],
          "submission_required": true,
          "typical_timeline_months": 6
        },
        "Class III": {
          "risk_level": "High",
          "requirements": [
            "GMP Certification",
            "Registration",
            "Technical File",
            "Clinical Evidence",
            "Biocompatibility Testing"
          ],
          "submission_required": true,
          "typical_timeline_months": 12
        },
        "Class IV": {
          "risk_level": "Very High",
          "requirements": [
            "GMP Certification",
            "Registration",
            "Technical File",
            "Clinical Investigation",
            "Additional Safety Testing"
          ],
          "submission_required": true,
          "typical_timeline_months": 18
        }
      },
      "special_programs": {
        "Accelerated Approval": {
          "description": "Fast-track for unmet medical needs",
          "timeline_reduction": "25%",
          "requirements": ["High unmet need", "No alternatives in Brazil"]
        }
      }
    },
    "Health_Canada": {
      "name": "Health Canada Medical Devices",
      "region": "Canada",
      "official_sources": [
        "https://www.canada.ca/en/health-canada.html",
        "https://laws-lois.justice.gc.ca/eng/acts/F-3.5/",
        "https://www.canada.ca/en/health-canada/services/medical-devices.html"
      ],
      "device_classifications": {
        "Class I": {
          "risk_level": "Low",
          "requirements": [
            "Medical Device Establishment License (MDEL)",
            "Device Licensing",
            "Labeling Requirements"
          ],
          "submission_required": false,
          "typical_timeline_months": 2
        },
        "Class II": {
          "risk_level": "Moderate",
          "requirements": [
            "MDEL or Medical Device License (MDL)",
            "Device License Application",
            "Quality Management System",
            "Pre-market Review"
          ],
          "submission_required": true,
          "typical_timeline_months": 4
        },
        "Class III": {
          "risk_level": "High",
          "requirements": [
            "Medical Device License (MDL)",
            "Device License Application",
            "Quality Management System",
            "Clinical Evidence",
            "Pre-market Approval"
          ],
          "submission_required": true,
          "typical_timeline_months": 8
        },
        "Class IV": {
          "risk_level": "Very High",
          "requirements": [
            "Medical Device License (MDL)",
            "Device License Application",
            "Quality Management System",
            "Clinical Investigation",
            "Detailed Pre-market Review"
          ],
          "submission_required": true,
          "typical_timeline_months": 12
        }
      },
      "special_programs": {
        "Priority Review": {
          "description": "Expedited review for innovative devices",
          "timeline_reduction": "30%",
          "requirements": ["Breakthrough technology", "Significant improvement"]
        }
      }
    }
  },
  "requirement_categories": {
    "quality_management": {
      "FDA": "21 CFR 820 (QSR)",
      "EU_MDR": "ISO 13485 + Article 10 requirements",
      "MFDS": "KGMP (Korean Good Manufacturing Practice)",
      "PMDA": "J-GMP (Japanese Good Manufacturing Practice)",
      "ANVISA": "RDC ANVISA 16/2013 (GMP)",
      "Health_Canada": "ISO 13485 + CMDR requirements"
    },
    "clinical_evaluation": {
      "FDA": "Clinical data for Class III/PMA",
      "EU_MDR": "MEDDEV 2.7.1 rev 4",
      "MFDS": "Clinical data for Class III/IV",
      "PMDA": "Clinical investigation for Class III/IV",
      "ANVISA": "Clinical evidence for Class III/IV",
      "Health_Canada": "Clinical data for Class III/IV"
    },
    "post_market_surveillance": {
      "FDA": "21 CFR 803, 806, 821, 822",
      "EU_MDR": "Articles 83-85, Annex XIII",
      "MFDS": "Post-market monitoring required",
      "PMDA": "Post-market safety monitoring",
      "ANVISA": "Vigilance system required",
      "Health_Canada": "Mandatory problem reporting"
    },
    "labeling": {
      "FDA": "21 CFR 801",
      "EU_MDR": "Article 23, Annex I",
      "MFDS": "MFDS labeling requirements",
      "PMDA": "PMDA labeling standards",
      "ANVISA": "RDC ANVISA requirements",
      "Health_Canada": "CMDR labeling requirements"
    }
  },
  "common_conflicts": [
    {
      "conflict_type": "Clinical Evidence Requirements",
      "description": "EU MDR requires more extensive clinical evidence than FDA 510(k)",
      "affected_markets": ["FDA", "EU_MDR"],
      "harmonization_strategy": "Generate comprehensive clinical evaluation report (CER) per MEDDEV 2.7.1 rev 4, then extract relevant portions for FDA 510(k)"
    },
    {
      "conflict_type": "Notified Body Availability",
      "description": "EU MDR requires Notified Body certification, limited capacity",
      "affected_markets": ["EU_MDR"],
      "harmonization_strategy": "Engage Notified Body 12-18 months before planned submission, consider parallel FDA submission"
    },
    {
      "conflict_type": "Local Clinical Data",
      "description": "Some markets require local clinical data",
      "affected_markets": ["PMDA", "MFDS"],
      "harmonization_strategy": "Plan multi-center clinical trials including sites in target markets, consider local data acceptance policies"
    },
    {
      "conflict_type": "Quality System Requirements",
      "description": "Different QSR standards with minor variations",
      "affected_markets": ["All"],
      "harmonization_strategy": "Implement comprehensive QMS covering ISO 13485, then add market-specific supplements"
    }
  ]
}
